Last reviewed · How we verify

Levofloxacin oral tablets — Competitive Intelligence Brief

Levofloxacin oral tablets (Levofloxacin oral tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone antibiotic. Area: Infectious Disease.

phase 3 Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levofloxacin oral tablets (Levofloxacin oral tablets) — GlaxoSmithKline. Levofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Levofloxacin oral tablets TARGET Levofloxacin oral tablets GlaxoSmithKline phase 3 Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV
Ofloxacin 0.3% Ofloxacin 0.3% Indiana University School of Medicine marketed Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV
Renamezin capsule Renamezin capsule Daewon Pharmaceutical Co., Ltd. marketed Fluoroquinolone antibiotic DNA gyrase, Topoisomerase IV
group-B : Levofloxacin triple therapy group-B : Levofloxacin triple therapy Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh marketed Fluoroquinolone antibiotic combination therapy Bacterial DNA gyrase, topoisomerase IV
Oral norfloxacin Oral norfloxacin Hospital Clinic of Barcelona marketed Fluoroquinolone antibiotic DNA gyrase, topoisomerase IV
besivance besivance Ophthalmology Consultants, Ltd. marketed DNA gyrase, Topoisomerase IV
Ciprofloxacin Tablets & Metronidazole tablets Ciprofloxacin Tablets & Metronidazole tablets MinaPharm Pharmaceuticals marketed Fluoroquinolone + Nitroimidazole antibiotic combination Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Fluoroquinolone antibiotic class)

  1. Bayer · 4 drugs in this class
  2. Allergan · 4 drugs in this class
  3. Mackay Memorial Hospital · 2 drugs in this class
  4. Indiana University School of Medicine · 2 drugs in this class
  5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 drug in this class
  6. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
  7. Connect Biopharma Australia Pty Ltd · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Global Alliance for TB Drug Development · 1 drug in this class
  10. Fundacion Clinic per a la Recerca Biomédica · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levofloxacin oral tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-oral-tablets. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: